PMID- 32678499
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 128
IP  - 12
DP  - 2020 Dec
TI  - Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate 
      diagnosis of mesothelial proliferations in effusion cytology.
PG  - 939-947
LID - 10.1002/cncy.22326 [doi]
AB  - BACKGROUND: A number of ancillary tests have been developed that aid in the 
      diagnosis of mesothelioma in cytology specimens. The aim of this retrospective 
      study was to determine whether testing for BAP1 and CDKN2A/p16 status in effusion 
      specimens preceding the tissue diagnosis of mesothelioma would improve diagnostic 
      accuracy and allow an earlier diagnosis of malignancy. METHODS: The study cohort 
      included 99 matched cytology fluid specimens from 74 patients with a surgical 
      specimen diagnosis of malignant mesothelioma (67 epithelioid, 7 biphasic, 55 
      pleural, and 19 peritoneal). BAP1 immunohistochemistry and p16 fluorescence in 
      situ hybridization (FISH) were performed retrospectively. RESULTS: BAP1 or p16 
      FISH testing revealed a loss in 7 of 18 (39%) samples originally categorized as 
      benign/reactive, 20 of 33 (61%) interpretable samples categorized as atypical, 
      and 10 of 14 (71%) cases suspicious for mesothelioma. In some cases, the 
      diagnosis of mesothelioma could have been made up to 9 months before biopsy. 
      Similarly, loss of BAP1 or p16 was found in 28 of 30 (93%) samples categorized as 
      malignant, with some cases diagnosable up to 6 months before biopsy. Overall, 
      loss of BAP1 and/or CDKN2A/p16 homozygous deletion would change the diagnostic 
      interpretation in 37 of 60 (62%) (P = .07) effusion specimens, particularly in 
      pleural effusions (32 of 48 samples) (P = .002). The sensitivity of morphologic 
      interpretation alone was 30.3%; however, adding testing for BAP1 and p16 resulted 
      in an increase in sensitivity to 68.7%. (P < .0001). CONCLUSION: These findings 
      suggest that routine use of BAP1 immunochemistry and p16 FISH as adjunctive tests 
      improves the diagnostic accuracy of cytology specimens and potentially allows an 
      earlier diagnosis of malignant mesothelioma.
CI  - (c) 2020 American Cancer Society.
FAU - Chevrier, Martin
AU  - Chevrier M
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Monaco, Sara E
AU  - Monaco SE
AUID- ORCID: 0000-0003-3039-4445
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Jerome, Jacob A
AU  - Jerome JA
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
FAU - Galateau-Salle, Francoise
AU  - Galateau-Salle F
AD  - Centre National Referent MESOPATH, Centre Leon Berard, Lyon, France.
FAU - Churg, Andrew
AU  - Churg A
AD  - Department of Pathology, Vancouver General Hospital and University of British 
      Columbia, Vancouver, British Columbia, Canada.
FAU - Dacic, Sanja
AU  - Dacic S
AUID- ORCID: 0000-0003-4197-3354
AD  - Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, 
      Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (BAP1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Cyclin-Dependent Kinase Inhibitor p16/*genetics
MH  - Cytodiagnosis/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Testing/methods
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Mesothelioma, Malignant/*diagnosis/genetics/surgery
MH  - Middle Aged
MH  - Peritoneal Neoplasms/diagnosis/genetics/surgery
MH  - Pleural Effusion/genetics/*pathology
MH  - Pleural Neoplasms/diagnosis/genetics/surgery
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Sequence Deletion
MH  - Tumor Suppressor Proteins/*genetics
MH  - Ubiquitin Thiolesterase/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - BAP1
OT  - cytopathology
OT  - effusion cytology
OT  - mesothelioma
OT  - p16
EDAT- 2020/07/18 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - 10.1002/cncy.22326 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2020 Dec;128(12):939-947. doi: 10.1002/cncy.22326. Epub 2020 
      Jul 17.